2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders
Stephen O’Brien(The University of Texas MD Anderson Cancer Center), MJ Keating(The University of Texas MD Anderson Cancer Center), Sherry Pierce(The University of Texas MD Anderson Cancer Center), Madeleine Duvic(The University of Texas MD Anderson Cancer Center), S Stass(The University of Texas MD Anderson Cancer Center), H. Kantarjian(The University of Texas MD Anderson Cancer Center), Razelle Kurzrock(Medical College of Wisconsin), L. E. Robertson(The University of Texas MD Anderson Cancer Center), Elihu H. Estey(University of Washington)
Cited by 63
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
|Journal of Clinical Oncology|2003|2.7k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
|Molecular Cancer Therapeutics|2017|2.4k